Home » Stocks » XFOR

X4 Pharmaceuticals, Inc. (XFOR)

Stock Price: $9.01 USD 0.29 (3.33%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 156.63M
Revenue (ttm) 3.00M
Net Income (ttm) -62.13M
Shares Out 20.08M
EPS (ttm) -3.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $9.01
Previous Close $8.72
Change ($) 0.29
Change (%) 3.33%
Day's Open 8.69
Day's Range 8.62 - 9.11
Day's Volume 82,822
52-Week Range 5.38 - 11.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR...

1 week ago - GlobeNewsWire

BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR...

2 weeks ago - GlobeNewsWire

BOSTON, March 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR...

4 weeks ago - GlobeNewsWire

2021 expected to be a year of key value-driving catalysts as company advances multiple  clinical programs with lead candidate mavorixafor

1 month ago - GlobeNewsWire

BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

2 months ago - GlobeNewsWire

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

3 months ago - GlobeNewsWire

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

3 months ago - GlobeNewsWire

X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

4 months ago - GlobeNewsWire

BOSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

4 months ago - GlobeNewsWire

BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

4 months ago - GlobeNewsWire

BOSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

5 months ago - GlobeNewsWire

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

BOSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of...

5 months ago - GlobeNewsWire

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

5 months ago - GlobeNewsWire

BOSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

6 months ago - GlobeNewsWire

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction...

7 months ago - GlobeNewsWire

Manuscript further details positive clinical results and long-term tolerability of mavorixafor in ongoing Phase 2 study

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunctio...

8 months ago - GlobeNewsWire

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Presentation of positive clinical data at EHA 2020 supporting the ongoing Phase 3 trial in WHIM syndrome

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunctio...

9 months ago - GlobeNewsWire

Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshold for abso...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunctio...

10 months ago - GlobeNewsWire

For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.

Other stocks mentioned: BTG, CSTM, DVAX, INVE, LIVX, OVID, PLUG ...
10 months ago - InvestorPlace

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq:  XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfuncti...

10 months ago - GlobeNewsWire

Arsanis Inc (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11 months ago - Zacks Investment Research

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

X4 Pharmaceuticals, Inc. (C) CEO Paula Ragan on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfo...

Other stocks mentioned: CDMO, ENDP, IGMS, ILMN, ISEE, KOD, MYL ...
1 year ago - 24/7 Wall Street

About XFOR

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa c... [Read more...]

Industry
Biotechnology
Founded
2014
Stock Exchange
NASDAQ
Ticker Symbol
XFOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price forecast is 19.29, which is an increase of 114.10% from the latest price.

Price Target
$19.29
(114.10% upside)
Analyst Consensus: Strong Buy